Login to Your Account

FDA Panel: Keep Avandia on Market With Restrictions

By Donna Young

Thursday, July 15, 2010
GAITHERSBURG, Md. – After two days of often very contentious debate over the validity and reliability of data from numerous studies of GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone), an FDA panel said in a split vote that the drug should remain on the U.S. market, but with new warnings about heart attacks and under limited use. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription